The FDA's Oncologic Drugs Advisory Committee Acknowledged AstraZeneca's Imfinzi (Durvalumab) Met Primary Endpoint Of Event-free Survival For Resectable Non-small Cell Lung Cancer Based On AEGEAN Phase 3 Trial Results With Overall Tolerable Safety Profile
Portfolio Pulse from Benzinga Newsdesk
The FDA's Oncologic Drugs Advisory Committee acknowledged that AstraZeneca's Imfinzi (Durvalumab) met the primary endpoint of event-free survival for resectable non-small cell lung cancer (NSCLC) in the AEGEAN Phase 3 trial. The trial showed a tolerable safety profile for patients treated with Imfinzi in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery.
July 26, 2024 | 10:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Imfinzi met the primary endpoint of event-free survival for resectable non-small cell lung cancer in the AEGEAN Phase 3 trial, with a tolerable safety profile. This acknowledgment by the FDA's Oncologic Drugs Advisory Committee could positively impact AstraZeneca's stock price in the short term.
The FDA's acknowledgment of Imfinzi meeting its primary endpoint in a significant trial for NSCLC is a positive development for AstraZeneca. This could lead to increased investor confidence and a potential rise in stock price due to the promising results and the tolerable safety profile of the drug.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100